Your browser is no longer supported. Please, upgrade your browser.
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E604.59 EPS (ttm)0.17 Insider Own1.00% Shs Outstand92.99M Perf Week-4.83%
Market Cap9.50B Forward P/E26.46 EPS next Y3.86 Insider Trans-22.54% Shs Float90.92M Perf Month-6.95%
Income21.10M PEG- EPS next Q0.73 Inst Own- Short Float4.66% Perf Quarter4.13%
Sales675.60M P/S14.06 EPS this Y113.70% Inst Trans0.06% Short Ratio4.43 Perf Half Y18.53%
Book/sh6.25 P/B16.35 EPS next Y402.86% ROA2.00% Target Price121.22 Perf Year14.39%
Cash/sh7.21 P/C14.18 EPS next 5Y- ROE4.30% 52W Range71.85 - 119.65 Perf YTD-4.94%
Dividend- P/FCF115.73 EPS past 5Y18.30% ROI4.20% 52W High-14.61% Beta1.51
Dividend %- Quick Ratio7.00 Sales past 5Y174.10% Gross Margin99.00% 52W Low42.21% ATR3.25
Employees585 Current Ratio7.10 Sales Q/Q46.30% Oper. Margin6.70% RSI (14)37.08 Volatility2.72% 2.90%
OptionableYes Debt/Eq0.00 EPS Q/Q6.80% Profit Margin3.10% Rel Volume0.73 Prev Close103.43
ShortableYes LT Debt/Eq0.70 EarningsFeb 04 AMC Payout0.00% Avg Volume956.63K Price102.18
Recom1.90 SMA20-5.54% SMA50-7.97% SMA2008.01% Volume695,303 Change-1.21%
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-07-18Initiated Stifel Buy $137
Feb-22-18Reiterated Needham Buy $95 → $110
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Jan-27-17Upgrade Oppenheimer Perform → Outperform
Nov-22-16Initiated Oppenheimer Perform
Nov-03-16Initiated Deutsche Bank Buy $65
Jan-20-20 04:30PM  Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results PR Newswire
10:02AM  Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta Zacks
Jan-17-20 08:22AM  Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks Zacks
Jan-13-20 08:30AM  Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update GlobeNewswire -8.37%
Jan-12-20 06:30PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones PR Newswire
Jan-10-20 11:40AM  AMRX vs. NBIX: Which Stock Is the Better Value Option? Zacks
01:00AM  Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy PR Newswire
Jan-09-20 12:10PM  Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report? Zacks
Jan-06-20 04:01PM  Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020 PR Newswire
10:31AM  Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Fair? Simply Wall St.
Dec-25-19 03:12PM  How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Dec-23-19 07:06PM  3 Breakout Stocks of the Last Decade to Consider for 2020 Zacks
01:01AM  S&P Rises for Fourth Straight Week Zacks
Dec-19-19 07:05AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-18-19 02:38PM  The Top 10 Stocks of the Past Decade Kiplinger
Dec-07-19 08:45AM  Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Dec-06-19 11:11AM  With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Is Interesting Simply Wall St.
Dec-03-19 07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 07:30AM  Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy GlobeNewswire
Nov-27-19 06:52AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-26-19 11:54PM  Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX) Insider Monkey
Nov-12-19 04:01PM  Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia PR Newswire
Nov-10-19 12:50AM  Edited Transcript of NBIX earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 04:01PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Nov-04-19 07:15PM  Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates Zacks
04:01PM  Neurocrine Biosciences Reports Third Quarter 2019 Financial Results PR Newswire
01:38PM  Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment? Simply Wall St.
Nov-01-19 08:53AM  Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX) Zacks
Oct-28-19 10:32AM  Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:30AM  CTLT vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Oct-22-19 03:56PM  Were Hedge Funds Right About Piling Into Neurocrine Biosciences (NBIX)? Insider Monkey
Oct-15-19 10:10AM  Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4 Zacks
Oct-14-19 04:59PM  Selling Tools to Miners: The Stocks That Can Profit on Biotech and Prosthetics GuruFocus.com
04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results PR Newswire
09:15AM  Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out? Zacks
Oct-10-19 09:30AM  CTLT or NBIX: Which Is the Better Value Stock Right Now? Zacks
Oct-04-19 06:00PM  Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress PR Newswire
Oct-01-19 04:01PM  Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress PR Newswire
Sep-30-19 04:01PM  Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer PR Newswire
Sep-27-19 11:26AM  Investors Who Bought Neurocrine Biosciences (NASDAQ:NBIX) Shares Five Years Ago Are Now Up 476% Simply Wall St.
Sep-18-19 09:31AM  Buy These 7 Small Drugmakers to Boost Your Portfolio's Health Zacks
Sep-17-19 04:11PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® PR Newswire
Sep-11-19 04:01PM  Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors PR Newswire
Sep-05-19 09:40AM  HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Sep-04-19 09:15AM  Lannett (LCI) Hits 52-Week High, Can the Run Continue? Zacks
Aug-28-19 04:01PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Aug-26-19 09:06AM  Is Neurocrine Biosciences (NBIX) a Great Growth Stock? Zacks
Aug-20-19 03:54PM  Edited Transcript of NBIX earnings conference call or presentation 29-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
08:33AM  Should You Be Worried About Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) 3.7% Return On Equity? Simply Wall St.
01:03AM  Another 1% Rally Provides a Strong Start to the Week Zacks
Aug-14-19 09:53AM  Why Neurocrine (NBIX) Could Be Positioned for a Surge Zacks
Aug-13-19 09:36AM  Moving Average Crossover Alert: Neurocrine Biosciences Zacks
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-09-19 09:25AM  Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks
08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 09:16PM  Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $7.6 million of Shares GuruFocus.com
Aug-07-19 11:20AM  Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 08:30AM  AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women PR Newswire
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
10:20AM  Why Neurocrine (NBIX) Might be Well Poised for a Surge Zacks
Jul-30-19 12:25PM  Why Neurocrine Biosciences Stock Is Jumping Today Motley Fool +10.33%
07:50AM  Dow Jones Futures: Beyond Meat Leads 5 Key Movers; Apple Earnings Loom Investor's Business Daily
06:00AM  Neurocrine Biosciences Posts Sizzling Sales Growth in Q2 Motley Fool
05:23AM  Neurocrine Biosciences Inc (NBIX) Q2 2019 Earnings Call Transcript Motley Fool
Jul-29-19 05:25PM  Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates Zacks
04:01PM  Neurocrine Biosciences Reports Second Quarter 2019 Financial Results PR Newswire
Jul-26-19 08:31AM  Should You Buy Neurocrine (NBIX) Ahead of Earnings? Zacks
Jul-22-19 07:28PM  8 Health-Care Stocks for Your Portfolio Kiplinger
10:31AM  Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-15-19 10:17AM  Does Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Reflect Performance? Simply Wall St.
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
06:17AM  The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug Benzinga
Jul-10-19 04:10PM  Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease PR Newswire
Jul-08-19 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results PR Newswire
Jun-11-19 04:01PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders PR Newswire
01:49PM  Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX) Insider Monkey
Jun-04-19 04:01PM  Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire
03:12AM  Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
May-31-19 11:51AM  Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount? Simply Wall St.
May-30-19 04:01PM  Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference PR Newswire +5.99%
May-29-19 09:15AM  Not Ready to Rally Zacks
May-21-19 08:00AM  AbbVie Launches ORILISSA (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
May-20-19 08:00AM  Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life PR Newswire
May-16-19 04:01PM  Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting PR Newswire
May-08-19 09:15AM  Trade Anxieties Return with a Vengeance Zacks
May-07-19 04:01PM  Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire
May-06-19 08:00AM  Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients PR Newswire
May-05-19 09:05AM  Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting PR Newswire
09:00AM  Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations PR Newswire
Apr-30-19 04:01PM  Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting PR Newswire -5.90%
08:06AM  The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering Benzinga
Apr-29-19 10:38PM  Neurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call Transcript Motley Fool
04:15PM  Neurocrine: 1Q Earnings Snapshot Associated Press
04:01PM  Neurocrine Biosciences Reports First Quarter 2019 Financial Results PR Newswire
Apr-26-19 06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-20-19 08:24PM  Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ? Insider Monkey
Apr-16-19 11:31AM  Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company? Simply Wall St.
Apr-08-19 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results PR Newswire
Apr-01-19 07:45AM  Recent Analysis Shows Coca-Cola, Neurocrine Biosciences, Worthington Industries, Lennox International, Barrett Business Services, and Balchem Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company's product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. also has a research collaboration agreement with Jnana Therapeutics Inc. to discover small molecule therapeutics for central nervous system disorders; a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson's disease and VY-FXN01 program for Friedreich's ataxia; and license and collaboration agreement with Xenon Pharmaceuticals Inc. for developing treatments for epilepsy. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBERTS EIRYChief Medical OfficerJan 08Sale111.112,632292,4455,991Jan 10 04:10 PM
ABERNETHY MATTChief Financial OfficerDec 02Sale116.331,645191,3603,876Dec 04 06:06 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Option Exercise35.995,000179,950113,408Nov 19 05:37 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Sale115.985,000579,900108,408Nov 19 05:37 PM
Lippoldt DarinChief Legal OfficerNov 08Option Exercise32.9910,000329,90026,728Nov 13 04:36 PM
LYONS GARY ADirectorNov 08Sale110.005,000550,000225,697Nov 13 04:41 PM
Lippoldt DarinChief Legal OfficerNov 08Sale110.0110,0001,100,05720,103Nov 13 04:36 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Option Exercise32.9910,188336,102118,596Nov 05 04:37 PM
LYONS GARY ADirectorNov 01Sale100.225,000501,104230,697Nov 05 04:38 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Sale100.3410,1881,022,298108,408Nov 05 04:37 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Option Exercise15.459,956153,82029,569Oct 16 04:20 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Sale90.859,956904,48719,613Oct 16 04:20 PM
Cooke JulieChief Human Resources OfficerOct 02Sale88.5698787,4093,276Oct 04 06:15 PM
Lippoldt DarinChief Legal OfficerSep 03Option Exercise32.996,736222,22126,839Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerSep 03Sale100.006,736673,60020,103Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerAug 27Option Exercise32.991,60052,78421,561Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 27Sale100.001,600160,00019,961Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Option Exercise32.991,66454,89521,625Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Sale100.091,664166,55519,961Aug 27 07:52 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 09Option Exercise32.993,03199,993420,628Aug 13 04:44 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Option Exercise8.6626,330228,018443,927Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Sale95.6426,3302,518,154417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Option Exercise8.662,75923,893420,356Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Sale95.122,759262,440417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Option Exercise8.6650,911440,889468,508Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Sale95.1550,9114,844,380417,597Aug 08 07:39 PM
Bozigian Haig P.Chief Development OfficerJul 30Option Exercise38.9144,3561,725,704167,576Jul 31 07:11 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Option Exercise32.9950,0001,649,500168,408Jul 31 07:12 PM
Lippoldt DarinChief Legal OfficerJul 30Option Exercise18.1515,831287,33335,792Jul 31 07:14 PM
LYONS GARY ADirectorJul 30Sale92.0710,000920,686235,697Jul 31 07:15 PM
Lippoldt DarinChief Legal OfficerJul 30Sale92.1315,8311,458,56919,961Jul 31 07:14 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Sale92.9260,0005,575,438108,408Jul 31 07:12 PM
Bozigian Haig P.Chief Development OfficerJul 30Sale92.7744,3564,114,858141,976Jul 31 07:11 PM
Bozigian Haig P.Chief Development OfficerJul 15Option Exercise32.9930,6801,012,133172,656Jul 17 07:08 PM
Bozigian Haig P.Chief Development OfficerJul 15Sale87.5030,6802,684,506141,976Jul 17 07:08 PM
BENEVICH ERICChief Commercial OfficerJul 15Sale87.445,835510,20114,910Jul 17 07:06 PM
Bozigian Haig P.Chief Development OfficerJul 11Option Exercise32.991003,299142,076Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 11Sale87.591008,759141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Option Exercise32.997,120234,889149,096Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Sale87.637,120623,958141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJun 18Option Exercise32.992,10069,279144,076Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 18Sale87.822,100184,417141,976Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 13Option Exercise20.7017,268357,469157,812Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 13Sale82.6217,2681,426,628141,976Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 03Option Exercise19.593,43567,292145,411Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerJun 03Sale85.513,435293,719141,976Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerMay 31Option Exercise19.5919,297378,028161,273Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 31Sale85.0219,2971,640,581141,976Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 24Option Exercise19.5917,486342,551159,462May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 24Sale80.0317,4861,399,434141,976May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 22Option Exercise19.591,30025,467143,276May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 22Sale80.031,300104,037141,976May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 16Option Exercise17.5866,6671,171,789176,352May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 16Sale80.1366,6675,341,893141,976May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 13Option Exercise8.6634,547299,177176,523May 15 07:23 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 13Sale75.441,657125,007118,408May 15 07:24 PM
Bozigian Haig P.Chief Development OfficerMay 13Sale75.5134,5472,608,813141,976May 15 07:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale83.5892076,89419,238Feb 08 05:11 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale84.0353144,622120,065Feb 08 05:09 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale83.5279166,06319,646Feb 08 05:10 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale84.234,096344,986417,597Feb 08 05:09 PM
Gano KyleChief Business Development OffFeb 06Sale83.5676263,67385,833Feb 08 05:07 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale83.5792076,88320,745Feb 08 05:06 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale83.5492076,859141,639Feb 08 05:06 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale88.141,272112,11916,574Feb 06 06:06 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale88.091,225107,91117,482Feb 06 06:05 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale88.171,07094,338118,322Feb 06 06:04 PM
Gano KyleChief Business Development OffFeb 05Sale88.122,434214,48280,989Feb 06 06:03 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale88.194,489395,895410,185Feb 06 06:03 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale88.011,357119,42717,595Feb 06 05:59 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale88.141,350118,986138,244Feb 06 05:59 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 04Sale88.121,375121,167117,066Feb 06 06:04 PM
Gano KyleChief Business Development OffFeb 04Sale88.141,375121,18680,117Feb 06 06:03 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 04Sale88.103,125275,321408,082Feb 06 06:03 PM
Bozigian Haig P.Chief Development OfficerFeb 04Sale88.101,375121,139137,372Feb 06 05:59 PM